scholarly article | Q13442814 |
P50 | author | Pierre U. Blier | Q46045677 |
P2093 | author name string | Maurizio Fava | |
Michael Liebowitz | |||
David Hough | |||
Pilar Lim | |||
Rosanne Lane | |||
Wayne C Drevets | |||
Husseini Manji | |||
Madhukar Trivedi | |||
Arun Ravindran | |||
Sheldon Preskorn | |||
Raphael Gaillard | |||
Maggie Fedgchin | |||
Jaskaran B Singh | |||
Ella J Daly | |||
Rama Melkote | |||
Dawn Vitagliano | |||
Hans Van Den Ameele | |||
P2860 | cites work | Morbidity in Depressive Disorders | Q47973002 |
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. | Q52587655 | ||
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. | Q64966336 | ||
Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) | Q74233384 | ||
General multistage gatekeeping procedures | Q79643921 | ||
Mixtures of multiple testing procedures for gatekeeping applications in clinical trials | Q83902220 | ||
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study | Q92165468 | ||
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class | Q92217233 | ||
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder | Q28291261 | ||
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire | Q33777234 | ||
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study | Q34506620 | ||
A brief measure for assessing generalized anxiety disorder: the GAD-7. | Q34529333 | ||
Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). | Q34733035 | ||
Diagnosis and definition of treatment-resistant depression | Q35111568 | ||
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. | Q35560309 | ||
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments | Q37197216 | ||
Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants | Q37246423 | ||
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. | Q37281749 | ||
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? | Q37439244 | ||
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. | Q37709437 | ||
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). | Q43273547 | ||
Assessing psychiatric impairment in primary care with the Sheehan Disability Scale | Q46084388 | ||
Physician Withdrawal Checklist (PWC-20). | Q46484513 | ||
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a | Q47198959 | ||
Adaptive sample size calculations in group sequential trials | Q47213254 | ||
Modification of sample size in group sequential clinical trials | Q47213272 | ||
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial | Q47667772 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P921 | main subject | treatment-resistant depression | Q7836891 |
P304 | page(s) | 616-630 | |
P577 | publication date | 2019-10-01 | |
P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
P1476 | title | Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) | |
P478 | volume | 22 |
Q96811669 | A systematic review of ketamine for the treatment of depression among older adults |
Q89842826 | Approval of esketamine for treatment-resistant depression |
Q89842828 | Approval of esketamine for treatment-resistant depression - Authors' reply |
Q98830300 | Benefit-Risk Assessment of Esketamine Nasal Spray versus Placebo in Treatment-Resistant Depression |
Q93020534 | Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program |
Q94450996 | Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui |
Q89626651 | Conformational flexibility within the small domain of human serine racemase |
Q94451007 | Esketamine clinical trials: reply to Maju et al |
Q92003437 | Esketamine for treatment resistant depression: a trick of smoke and mirrors? |
Q91077725 | Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval |
Q98386641 | Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review |
Q98158719 | Genome-wide association study and polygenic risk score analysis of esketamine treatment response |
Q95642618 | Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers |
Search more.